Sagimet Biosciences (STU:0O2) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Sagimet Biosciences Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Sagimet Biosciences's annualized Gross Profit for the quarter that ended in Dec. 2024 was €0.00 Mil. Sagimet Biosciences's average Total Assets over the quarter that ended in Dec. 2024 was €155.26 Mil. Therefore, Sagimet Biosciences's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 0.00%.

Sagimet Biosciences Gross-Profit-to-Asset % Historical Data

The historical data trend for Sagimet Biosciences's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sagimet Biosciences Gross-Profit-to-Asset % Chart

Sagimet Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

3.06

Sagimet Biosciences Quarterly Data
	Dec19	Mar20	Dec20	Mar21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial												-	-	-	-	-

Competitive Comparison of Sagimet Biosciences's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Sagimet Biosciences's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sagimet Biosciences's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Sagimet Biosciences's Gross-Profit-to-Asset % falls into.

Save Embed

;

Save Embed

;

Sagimet Biosciences Gross-Profit-to-Asset % Calculation

Sagimet Biosciences's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2024 )	/	( (Total Assets (A: Dec. 2023 )	+	Total Assets (A: Dec. 2024 ))	/ count )
	=	0	/	( (88.691	+	153.047)	/ 2 )
	=	0	/	120.869
	=	0.00 %

Sagimet Biosciences's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2024 )	/	( (Total Assets (Q: Sep. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	0	/	( (157.472	+	153.047)	/ 2 )
	=	0	/	155.2595
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Sagimet Biosciences Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Sagimet Biosciences's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sagimet Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sagimet Biosciences Inc (STU:0O2) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

SGMT:USA 0O2:Germany

Address

155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402

Website

https://www.sagimet.com

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Sagimet Biosciences Headlines

No Headlines